Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PharmaCyte BiotechPMCB -4.55%34 ROA % is -34.24% as of Apr. 2026. GuruFocus rates PMCB with a GF Score™ of 34/100. The stock has 2 warning signs investors should review. Among 1,410 Biotechnology companies, PharmaCyte Biotech ranks worse than 53.83% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. PharmaCyte Biotech's annualizedNet Income for the quarter that ended in Apr. 2026 was $-17.57 Mil.
PharmaCyte Biotech's average Total Assets over the quarter that ended in Apr. 2026 was $51.31 Mil. Therefore, PharmaCyte Biotech's annualized ROA % for the quarter that ended in Apr. 2026 was -34.24%.
The historical rank and industry rank for PharmaCyte Biotech's ROA % or its related term are showing as below:
PMCB'
s ROA % Range Over the Past 10 Years
Min: -90.57 Med: -45.23 Max: 53.28
Current: -37.52
During the past 13 years, PharmaCyte Biotech's highest ROA % was 53.28%. The lowest was -90.57%. And the median was -45.23%.
PMCB's ROA % is ranked worse than 53.83% of 1410
companies
in the Biotechnology industry
Industry Median: -33.225
vs PMCB: -37.52
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Apr. 2026) net income data. The Revenue data used here is four times the quarterly (Apr. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
PharmaCyte Biotech ROA % Related Terms
PharmaCyte Biotech ROA % Historical Data
* Premium members only.
The historical data trend for PharmaCyte Biotech's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, PharmaCyte Biotech's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PharmaCyte Biotech ROA % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PharmaCyte Biotech's ROA % distribution charts can be found below:
* The bar in red indicates where PharmaCyte Biotech's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Apr. 2026) net income data.
ROA % is displayed in the 30-year financial page.
PharmaCyte Biotech (PMCB) has a ROA % of -34.24% as of Apr. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on PharmaCyte Biotech and its competitors. According to the industry distribution chart, PharmaCyte Biotech ranks #759 out of 1410 companies in the Biotechnology industry, placing it in the top 53.8%.
Is PharmaCyte Biotech's ROA % too high?
PharmaCyte Biotech's current ROA % is -34.24%. Based on the distribution chart, PharmaCyte Biotech ranks #759 out of 1410 companies in the Biotechnology industry, which is below the industry midpoint. Overall, PharmaCyte Biotech has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does PharmaCyte Biotech's ROA % compare to NIKI and IMNN?
According to the Biotechnology industry distribution chart, PharmaCyte Biotech ranks #759 out of 1410 companies for ROA %. This places PharmaCyte Biotech in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Biotechnology company?
A good ROA % depends on the Biotechnology industry context. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on PharmaCyte Biotech and its competitors. PharmaCyte Biotech's current ROA % is -34.24%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaCyte Biotech stock overvalued right now?
PharmaCyte Biotech (PMCB) has a current ROA % of -34.24%. The current ROA % is -34.24%. PharmaCyte Biotech's overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For PharmaCyte Biotech (PMCB), the current ROA % is -34.24% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
34GF Score
Get the complete analysis for PMCB
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PMCB has been successfully added to your 
